Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John L Johnson

Showing results (91-100 of 108) with videos related to

Pageof 11
Sort By:
The Journal of Infectious Diseases|August 2, 2012
Substitution of rifapentine for rifampin during intensive phase treatment of pulmonary tuberculosis: study 29 of the tuberculosis trials consortiumSusan E Dorman, Stefan Goldberg, Jason E Stout, et al.
Journal of Immunology (Baltimore, Md. : 1950)|October 16, 2019
MR1-Independent Activation of Human Mucosal-Associated Invariant T Cells by MycobacteriaSara Suliman, Melissa Murphy, Munyaradzi Musvosvi, et al.
American Journal of Respiratory and Critical Care Medicine|May 2, 2009
Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosisSusan E Dorman, John L Johnson, Stefan Goldberg, et al.
American Journal of Respiratory and Critical Care Medicine|December 10, 2014
Daily rifapentine for treatment of pulmonary tuberculosis. A randomized, dose-ranging trialSusan E Dorman, Radojka M Savic, Stefan Goldberg, et al.
JCI Insight|February 8, 2024
Gene coexpression networks reveal a broad role for lncRNAs in inflammatory bowel diseaseJohn L Johnson, Davit Sargsyan, Eric M Neiman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 28, 2009
Dose-modified oral chemotherapy in the treatment of AIDS-related non-Hodgkin's lymphoma in East AfricaWalter O Mwanda, Jackson Orem, Pingfu Fu, et al.
American Journal of Respiratory and Critical Care Medicine|July 9, 2011
CDC/NIH Workshop. Tuberculosis biomarker and surrogate endpoint research roadmapPayam Nahid, Jussi Saukkonen, William R Mac Kenzie, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 30, 2022
Rifapentine With and Without Moxifloxacin for Pulmonary Tuberculosis in People With Human Immunodeficiency Virus (S31/A5349)April C Pettit, Patrick P J Phillips, Ekaterina Kurbatova, et al.
Plos Pathogens|November 18, 2017
Sequential inflammatory processes define human progression from M. tuberculosis infection to tuberculosis diseaseThomas J Scriba, Adam Penn-Nicholson, Smitha Shankar, et al.
Ebiomedicine|February 12, 2022
Effects of BCG vaccination on donor unrestricted T cells in two prospective cohort studiesAnele Gela, Melissa Murphy, Miguel Rodo, et al.
Pageof 11

Showing results (91-100 of 108) with videos related to

Sort By:
Pageof 11
The Journal of Infectious Diseases|August 2, 2012
Substitution of rifapentine for rifampin during intensive phase treatment of pulmonary tuberculosis: study 29 of the tuberculosis trials consortiumSusan E Dorman, Stefan Goldberg, Jason E Stout, et al.
Journal of Immunology (Baltimore, Md. : 1950)|October 16, 2019
MR1-Independent Activation of Human Mucosal-Associated Invariant T Cells by MycobacteriaSara Suliman, Melissa Murphy, Munyaradzi Musvosvi, et al.
American Journal of Respiratory and Critical Care Medicine|May 2, 2009
Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosisSusan E Dorman, John L Johnson, Stefan Goldberg, et al.
American Journal of Respiratory and Critical Care Medicine|December 10, 2014
Daily rifapentine for treatment of pulmonary tuberculosis. A randomized, dose-ranging trialSusan E Dorman, Radojka M Savic, Stefan Goldberg, et al.
JCI Insight|February 8, 2024
Gene coexpression networks reveal a broad role for lncRNAs in inflammatory bowel diseaseJohn L Johnson, Davit Sargsyan, Eric M Neiman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 28, 2009
Dose-modified oral chemotherapy in the treatment of AIDS-related non-Hodgkin's lymphoma in East AfricaWalter O Mwanda, Jackson Orem, Pingfu Fu, et al.
American Journal of Respiratory and Critical Care Medicine|July 9, 2011
CDC/NIH Workshop. Tuberculosis biomarker and surrogate endpoint research roadmapPayam Nahid, Jussi Saukkonen, William R Mac Kenzie, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 30, 2022
Rifapentine With and Without Moxifloxacin for Pulmonary Tuberculosis in People With Human Immunodeficiency Virus (S31/A5349)April C Pettit, Patrick P J Phillips, Ekaterina Kurbatova, et al.
Plos Pathogens|November 18, 2017
Sequential inflammatory processes define human progression from M. tuberculosis infection to tuberculosis diseaseThomas J Scriba, Adam Penn-Nicholson, Smitha Shankar, et al.
Ebiomedicine|February 12, 2022
Effects of BCG vaccination on donor unrestricted T cells in two prospective cohort studiesAnele Gela, Melissa Murphy, Miguel Rodo, et al.
Pageof 11